Projects per year
Search results
-
Active
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), AnEGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with UnresectableLocally Advanced or Metastatic Cancer
TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
9/28/23 → 5/31/33
Project: Research project
-
Novel Immunotherapy Targeting IGF1R/IR in TNBC
V FOUNDATION FOR CANCER RESEARCH
3/15/22 → 4/21/24
Project: Research project
-
A Global Phase 2 Study to Evaluate the Efficacy andSafety of ARX788 for Selected HER2-mutated orHER2-amplified/over-expressed Solid Tumors
3/4/22 → 3/31/27
Project: Research project
-
-
Phase III Study Evaluating Palbociclib (PD-0332991), a C
NAT'L SURGICAL ADJ BREAST & BOWEL PROJ., PFIZER, INC.
3/1/15 → 5/1/24
Project: Research project
-
Finished
Natural Killer Cell Mediated Immunotherapy for Hormone Receptor Positive Metastatic Breast Cancer
Sachdev, D., Beckwith, H. C., Felices, M. & Hackel, B.
MAYO CLINIC ROCHESTER, NATIONAL INSTITUTES OF HEALTH (NIH)
9/1/20 → 8/31/22
Project: Research project
-
A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast can
BOEHRINGER-INGELHEIM PHARMACEUTICALS
8/30/18 → 8/30/23
Project: Research project
-